Treatment of residual disease following neoadjuvant therapy in breast cancer.
Natalie K HeaterKhyati SomayajiWilliam GradisharPublished in: Journal of surgical oncology (2023)
Substantial advances have been made in the systemic treatment of breast cancer with residual disease following neoadjuvant therapy. We reviewed recent and ongoing studies informing the standard clinical management of residual disease by subtype: HER2+, TNBC, and HR+/HER2-, as well as strategies for BRCA+ disease. We conclude with a discussion of ongoing clinical trials and current controversies regarding the treatment of residual disease in breast cancer.